Cogstate Ltd
CGS.ASXHealth Care
Cogstate Ltd (ASX:CGS) is the neuroscience company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.
Market Data
$2.635
-0.0%$460.5M
31.2x
$0.088
0.74%
+0.2%
Latest Earnings
Cogstate 1H26 Financial Results
19 February 2026
Cogstate delivered strong 1H26 results with revenue up 12% to $26.9M and net profit up 16% to $4.5M, driven by record clinical trial contract wins of $41.7M (up 105%). The company demonstrated operational leverage and diversification success with 45% of new contracts from mood, sleep and neurological conditions beyond Alzheimer's disease. Key points: Record clinical trial sales contracts of $41.7M, up 105% on pcp; Strong diversification with 45% of contracts from mood/sleep/neurological conditions (6x increase); Contracted future revenue increased to $104.9M with record $21.7M expected in 2H26
Recent Announcements
Earnings Release - 18 August 2026
Upcoming earnings release expected 18 August 2026 (from Yahoo Finance (confirmed))
Cogstate 1H26 Financial Results
Cogstate delivered strong 1H26 results with revenue up 12% to $26.9M and net profit up 16% to $4.5M, driven by record clinical trial contract wins of $41.7M (up 105%). The company demonstrated operational leverage and diversification success with 45% of new contracts from mood, sleep and neurological conditions beyond Alzheimer's disease. Key points: Record clinical trial sales contracts of $41.7M, up 105% on pcp; Strong diversification with 45% of contracts from mood/sleep/neurological conditions (6x increase); Contracted future revenue increased to $104.9M with record $21.7M expected in 2H26
Get real-time alerts for CGS
Receive AI-powered earnings summaries and instant notifications when Cogstate Ltd releases results.
Register Free